Industry News

Sapropterin has become an important therapeutic option for individuals living with phenylketonuria (PKU), especially patients who retain some residual phenylalanine hydroxylase activity. This medication helps reduce phenylalanine levels in the blood, allowing improved metabolic control and potentially a less restrictive diet for certain patients.

Pralatrexate is a folic acid analogue metabolism inhibitor, belonging to the antifolate chemotherapy class. It is primarily used to treat adult patients with relapsed or refractory peripheral T-cell lymphoma (R/R PTCL).

Zanubrutinib is a novel BTK (Bruton's tyrosine kinase) inhibitor independently developed by BeiGene in China. It belongs to the small-molecule targeted anti-tumor drug category.

Carfilzomib is a targeted anti-tumor drug, belonging to the class of irreversible proteasome inhibitors, primarily used to treat relapsed or refractory multiple myeloma (RRMM).

Upatinib is an orally administered, highly selective JAK1 inhibitor, a small-molecule targeted therapy primarily used to treat various immune-mediated chronic inflammatory diseases.